ETNB 89bio
- 9.140
- +1.360+17.48%
- 8.710
- -0.430-4.70%
89bio News
Madrigal, 89Bio Jump After Novo's Semaglutide Shows Promise in MASH
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
State Street Corp's Strategic Acquisition in 89bio Inc
89bio to Present New Analyses From ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024
89bio Negotiates $50 Million Increase in Borrowing Capacity to $150 Million
Express News | 89Bio Inc: Term Loan Matures on October 1, 2028
Express News | 89Bio Inc: Co and Certain Units Entered Into Amendment to Loan and Security Agreement
89bio (NASDAQ:ETNB) Has Debt But No Earnings; Should You Worry?
Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target
89bio Analyst Ratings
Press Release: 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
Express News | 89Bio Announces Appointment of Teresa Perney, Ph.d. as Chief Regulatory and Quality Officer
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
89bio to Participate in Upcoming Investor Conferences
Express News | 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Welcomes New COO Francis Sarena With Robust Compensation
89bio Names Francis Sarena as COO
Express News | 89Bio Appoints Francis Sarena as Chief Operating Officer
Leerink Partners Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $34
Leerink Partners analyst Thomas Smith maintains $89bio(ETNB.US)$ with a buy rating, and maintains the target price at $34.According to TipRanks data, the analyst has a success rate of 46.5% and a
Analysis
Price Target
No Data
No Data
